The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy

A single amino acid substitution in hemoglobin comprises the molecular basis for sickle cell anemia, but evolution of the corresponding clinical disease is extraordinarily complicated and likely involves multiple pathogenic factors. Sickle disease is fundamentally an inflammatory state, with activation of the endothelium, probably through proximate effects of reperfusion injury physiology and chronic molestation by adherent red cells and white cells. The disease also involves enhanced angiogenic propensity, activation of coagulation, disordered vasoregulation, and a component of chronic vasculopathy. Sickle cell anemia is truly an endothelial disease, and it is likely that genetic differences in endothelial function help govern its astonishing phenotypic diversity.

[1]  Jinming Huang,et al.  Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. , 2002, Journal of the American Chemical Society.

[2]  J. Eckman,et al.  Thrombogenesis in sickle cell disease. , 2001, The Journal of laboratory and clinical medicine.

[3]  J. Bischof,et al.  Transgenic sickle mice have vascular inflammation. , 2003, Blood.

[4]  E. Verrier The vascular endothelium: friend or foe? , 1993, The Annals of thoracic surgery.

[5]  Jenifer L. Breshears Silent Cerebral Infarcts in Sickle Cell Anemia: A Risk Factor Analysis. , 2000 .

[6]  L. McIntire,et al.  Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. , 1996, Blood.

[7]  D. Winter,et al.  Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. , 2001, The Journal of surgical research.

[8]  R. Hebbel,et al.  Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. , 2003, Blood.

[9]  R. Hebbel,et al.  Sickle Cell Disease: Basic Principles and Clinical Practice , 1994 .

[10]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.

[11]  G. Vercellotti,et al.  Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. , 2000, Blood.

[12]  V. Kalra,et al.  Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. , 1998, Blood.

[13]  D. S. Mcleod,et al.  Angiogenic factors in human proliferative sickle cell retinopathy , 1999, The British journal of ophthalmology.

[14]  Scott T. Miller,et al.  Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. , 1999, Pediatrics.

[15]  D. D. Shock,et al.  Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. , 1996, Blood.

[16]  J. Grande,et al.  Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. , 2001, The American journal of pathology.

[17]  E. Wayner,et al.  Circulating activated endothelial cells in sickle cell anemia. , 1997, The New England journal of medicine.

[18]  F. Pavalko,et al.  Vascular endothelial cell activation and permeability responses to thrombin. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[19]  J. White,et al.  Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. , 1980, The Journal of clinical investigation.

[20]  J. Castaigne,et al.  Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. , 1984, Agents and actions. Supplements.

[21]  Steven M Holland,et al.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.

[22]  E. Wayner,et al.  Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia , 1993 .

[23]  A. Koch,et al.  Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. , 1999, Arthritis and rheumatism.

[24]  A. Kumar,et al.  Inhibition of plasma‐mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD‐containing peptides , 1996, American journal of hematology.

[25]  A. Duits,et al.  Neutrophil activation in sickle cell disease , 1999, Journal of leukocyte biology.

[26]  R. Adams,et al.  Sickle cell disease: The neurological complications , 2002, Annals of neurology.

[27]  J. White,et al.  Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. , 1987, Blood.

[28]  J. Panepinto,et al.  Pathophysiology of Stroke in Sickle Cell Disease , 2004, Microcirculation.

[29]  F. Kuypers,et al.  Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. , 2000, Blood.

[30]  A. Varki,et al.  Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. , 2002, Blood.

[31]  M. Endres,et al.  Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice , 2002, Brain Research.

[32]  B. Setty,et al.  Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. , 2002, Blood.

[33]  R. Nagel,et al.  Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. , 2000, Blood.

[34]  S. Embury The Not‐So‐Simple Process of Sickle Cell Vasoocclusion , 2004, Microcirculation.

[35]  G. Wise,et al.  Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures. , 1979, Blood.

[36]  A. Grigg,et al.  Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. , 2001, Blood.

[37]  J. Witztum,et al.  Epoxyisoprostane and Epoxycyclopentenone Phospholipids Regulate Monocyte Chemotactic Protein-1 and Interleukin-8 Synthesis , 2002, The Journal of Biological Chemistry.

[38]  J. Gore,et al.  Demonstration of endothelial adhesion of sickle cells in vivo: a distinct role for deformable sickle cell discocytes. , 1992, Blood.

[39]  N. Perelman,et al.  Placenta growth factor activates monocytes and correlates with sickle cell disease severity. , 2003, Blood.

[40]  O. Castro,et al.  The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. , 1994, Blood.

[41]  M. Khademi,et al.  Renal angiography in sickle-cell disease. A preliminary report correlating the angiographic and urographic changes in sickle-cell nephropathy. , 1973, Radiology.

[42]  L. McIntire,et al.  Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. , 2000, Blood.

[43]  E. Vichinsky,et al.  Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. , 1997, Blood.

[44]  G. Merault,et al.  Morphological features of the human umbilical vein in normal, sickle cell trait, and sickle cell disease pregnancies. , 1999, Human pathology.

[45]  M. Gladwin,et al.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. , 2003, The Journal of clinical investigation.

[46]  L. McIntire,et al.  Sickle erythrocytes increase prostacyclin and endothelin‐1 production by cultured human endothelial cells under flow conditions , 2002, European journal of haematology.

[47]  C. Dampier,et al.  Arachidonic acid metabolites are involved in mediating red blood cell adherence to endothelium. , 1995, The Journal of laboratory and clinical medicine.

[48]  J. Scott,et al.  Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. , 1996, Blood.

[49]  Scott T. Miller,et al.  Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.

[50]  C. Moertel,et al.  Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. , 1998, Blood.

[51]  J. Eckman,et al.  Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. , 1993, Blood.

[52]  A. Duits,et al.  Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. , 1996, Clinical immunology and immunopathology.

[53]  R. Hebbel,et al.  Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. , 1999, Biochimica et biophysica acta.

[54]  R. Rojer,et al.  Molgramostim to treat SS-sickle cell leg ulcers , 1995, The Lancet.

[55]  M. Gladwin,et al.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. B. Alexander,et al.  Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. , 2003, The Journal of biological chemistry.

[57]  D. S. Mcleod,et al.  Inhibition of TNF-α–induced Sickle RBC Retention in Retina by a VLA-4 Antagonist , 2001 .

[58]  Richard A.O. Montes,et al.  Sickle erythrocyte adherence to endothelium at low shear: Role of shear stress in propagation of vaso‐occlusion , 2002, American journal of hematology.

[59]  K. Pritchard,et al.  L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease , 2003, Circulation.

[60]  H. Hydén,et al.  A receptor for phosphatidylserine-specific clearance of apoptotic cells , 2000, Nature.

[61]  J. Eckman,et al.  Double-stranded RNA induces sickle erythrocyte adherence to endothelium: a potential role for viral infection in vaso-occlusive pain episodes in sickle cell anemia. , 1995, Blood.

[62]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[63]  J. Greenberg,et al.  Trial of low doses of aspirin as prophylaxis in sickle cell disease. , 1983, The Journal of pediatrics.

[64]  M. Boisseau,et al.  [Hemostasis]. , 2020, Revue de laryngologie - otologie - rhinologie.

[65]  B. Ewenstein,et al.  Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. , 1999, Blood.

[66]  G. Kojda,et al.  Vasoprotection by nitric oxide: mechanisms and therapeutic potential. , 2002, Cardiovascular research.

[67]  H. Meiselman,et al.  Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. , 1996, Blood.

[68]  B. Setty,et al.  Thrombophilia in sickle cell disease: the red cell connection. , 2001, Blood.

[69]  P. Frenette Sickle Cell Vasoocclusion: Heterotypic, Multicellular Aggregations Driven by Leukocyte Adhesion , 2004, Microcirculation.

[70]  H. Farber,et al.  Endothelin-1 production during the acute chest syndrome in sickle cell disease. , 1997, American journal of respiratory and critical care medicine.

[71]  R. Korthuis,et al.  Physiologic mechanisms of postischemic tissue injury. , 1995, Annual review of physiology.

[72]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.

[73]  J. Dachary-Prigent,et al.  Phosphatidylserine‐related adhesion of human erythrocytes to vascular endothelium , 1999, British journal of haematology.

[74]  J. Scott,et al.  Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin , 2000, British journal of haematology.

[75]  E. Rubin,et al.  In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. , 1995, The Journal of clinical investigation.

[76]  D. Lefer,et al.  Sexual dimorphism in reduced-size liver ischemia and reperfusion injury in mice: Role of endothelial cell nitric oxide synthase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[77]  D. Lefer,et al.  Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. , 1998, Free radical biology & medicine.

[78]  P. Hogg,et al.  Control of Von Willebrand Factor Multimer Size by Thrombospondin-1 , 2001, The Journal of experimental medicine.

[79]  A. Varki,et al.  P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. , 2001, Blood.

[80]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[81]  P. Klug,et al.  Endothelial cell and vascular damage in the sickle cell disorders. , 1982, Blood cells.

[82]  R. Hebbel,et al.  CD36-positive stress reticulocytosis in sickle cell anemia. , 1996, The Journal of laboratory and clinical medicine.

[83]  J. Loscalzo,et al.  Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. , 2000, Circulation.

[84]  R. Nagel,et al.  Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist. , 2001, Investigative ophthalmology & visual science.

[85]  S. Raines,et al.  Priapism associated with sickle cell disease. , 1962, The Journal of urology.

[86]  S. Hazen,et al.  Peroxidases inhibit nitric oxide (NO) dependent bronchodilation: development of a model describing NO-peroxidase interactions. , 2001, Biochemistry.

[87]  A. Duits,et al.  Levels of Endothelial, Neutrophil and Platelet-Specific Factors in Sickle Cell Anemia Patients during Hydroxyurea Therapy , 1999, Acta Haematologica.

[88]  T. Wun,et al.  Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. , 2002, Clinical and laboratory haematology.

[89]  G. Vercellotti,et al.  Reperfusion injury pathophysiology in sickle transgenic mice. , 2000, Blood.

[90]  M. Gladwin,et al.  The Perfusion Paradox and Vascular Instability in Sickle Cell Disease , 2004, Microcirculation.

[91]  J. Hofrichter,et al.  A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. , 1996, Blood.

[92]  S. Sowemimo-Coker,et al.  Effects of normal and sickle erythrocytes on prostacyclin release by perfused human umbilical cord veins , 1992, American journal of hematology.

[93]  K. Preissner,et al.  Vascular protease receptors: integrating haemostasis and endothelial cell functions , 2000, The Journal of pathology.

[94]  J. Morris,et al.  Stroke in a cohort of patients with homozygous sickle cell disease. , 1992, The Journal of pediatrics.

[95]  J. Stuart,et al.  Subclinical ischaemic episodes during the steady state of sickle cell anaemia. , 1992, Journal of clinical pathology.

[96]  L. Parise,et al.  Integrin-associated protein is an adhesion receptor on sickle red blood cells for immobilized thrombospondin. , 2001, Blood.

[97]  J. Maclouf,et al.  Release of prostacyclin after erythrocyte adhesion to cultured vascular endothelium. , 1986, The Journal of laboratory and clinical medicine.

[98]  C. Pegelow,et al.  Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. , 2002, The Journal of pediatrics.

[99]  J. Moake,et al.  Unusually large von willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells , 1993, American journal of hematology.

[100]  R. Hebbel,et al.  Modulation of endothelial cell activation in sickle cell disease: a pilot study. , 2001, Blood.

[101]  R. Hebbel,et al.  Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis , 2004, Angiogenesis.

[102]  R. Silverstein,et al.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. , 2001, The Journal of clinical investigation.

[103]  J. Scott,et al.  The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. , 1999, Blood.

[104]  A. Shah Vascular endothelium. , 1992, British journal of hospital medicine.

[105]  B. Setty,et al.  Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. , 1999, Blood.

[106]  P. Gane,et al.  The nonexpression of CD 36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia , 2001 .

[107]  M L Terrin,et al.  Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent , 1996, Medicine.

[108]  D. Ribatti,et al.  Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. , 1999, Blood.

[109]  G. Truskey,et al.  Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. , 1998, The Journal of clinical investigation.

[110]  R. Hebbel,et al.  Disturbance of plasma and platelet thrombospondin levels in sickle cell disease , 1996, American journal of hematology.

[111]  C. Thomas,et al.  Vascular lesions in the central nervous system in sickle cell disease (neuropathology). , 1990, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[112]  R. Nagel,et al.  Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. , 1993, Blood.

[113]  J. Zhan,et al.  Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. , 1994, Blood.

[114]  T. Pearson,et al.  Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. , 1998, Blood.

[115]  C. Srodes,et al.  An unusual pattern of neutrophil kinetics in sickle cell anemia. , 1973, Blood.

[116]  W. Murphy,et al.  Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. , 1989, East African medical journal.

[117]  J. Lawler,et al.  Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. , 1997, Blood.

[118]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[119]  R. Schmid,et al.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. , 1998, The Journal of clinical investigation.

[120]  R. Hebbel,et al.  Tissue factor expression by endothelial cells in sickle cell anemia. , 1998, The Journal of clinical investigation.

[121]  J. Geng,et al.  N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo , 2002, Inflammation Research.

[122]  J. Prchal,et al.  Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. , 2001, Blood.

[123]  R. Weinstein,et al.  Sickle erythrocytes inhibit human endothelial cell DNA synthesis. , 1990, Blood.

[124]  D. Yee,et al.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. , 2002, Cancer research.

[125]  M. Mosseri,et al.  Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. , 1993, American heart journal.

[126]  H. Cate,et al.  Low‐intensity oral anticoagulation in sickle‐cell disease reverses the prethrombotic state: promises for treatment? , 1995, British journal of haematology.

[127]  R. Hebbel,et al.  Autoxidation, dehydration, and adhesivity may be related abnormalities of sickle erythrocytes. , 1989, The American journal of physiology.

[128]  S. Albelda,et al.  Integrins and other cell adhesion molecules , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[129]  B. Setty,et al.  Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol. , 1996, The Journal of laboratory and clinical medicine.

[130]  F. Mach,et al.  Statins: the new aspirin? , 2002, Cellular and Molecular Life Sciences CMLS.

[131]  M. Gladwin,et al.  Divergent Nitric Oxide Bioavailability in Men and Women With Sickle Cell Disease , 2003, Circulation.

[132]  L. Parise,et al.  Sickle cell adhesion to laminin : Potential role for the α5 chain , 1998 .

[133]  L. Parise,et al.  Sickle cell adhesion to laminin: potential role for the alpha5 chain. , 1998, Blood.

[134]  F. Galactéros,et al.  Fibrinogen, a modulator of erythrocyte adhesion to vascular endothelium. , 1983, The Journal of laboratory and clinical medicine.

[135]  J. Eaton,et al.  Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. , 1980, The New England journal of medicine.

[136]  P. V. Ichinsky,et al.  Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease , 2000 .

[137]  J. Stuart,et al.  Effects of density and of dehydration of sickle cells on their adhesion to cultured endothelial cells , 1996, American journal of hematology.

[138]  D. McIntire,et al.  High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. , 1994, The New England journal of medicine.

[139]  R. Nagel,et al.  Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell–endothelium interactions induced by platelet-activating factor , 2000 .

[140]  K. Ataga,et al.  Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. , 2001, JAMA.

[141]  W. Frazier Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cells , 1987, The Journal of cell biology.

[142]  M. Hughson,et al.  Pulmonary thrombotic arteriopathy in patients with sickle cell disease. , 2001, Archives of pathology & laboratory medicine.

[143]  J. Elion,et al.  Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. , 2002, Blood.

[144]  J. Salvaggio,et al.  Long-term anti-coagulation in sickle-cell disease. A clinical study. , 1963, The New England journal of medicine.

[145]  J. Eckman,et al.  Sickle erythrocyte adherence to large vessel and microvascular endothelium under physiologic flow is qualitatively different. , 1992, The Journal of laboratory and clinical medicine.

[146]  R. Hebbel,et al.  Amendment history : Erratum ( September 2000 ) Hypoxia / reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice , 2018 .

[147]  J. Reisch,et al.  Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. , 1998, Blood.

[148]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[149]  M. Telfer,et al.  Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. , 1998, Blood.

[150]  P. Adegboyega,et al.  Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. , 2002, Human pathology.

[151]  M. Ho,et al.  Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow. , 2000, Blood.

[152]  F. Kirkham,et al.  Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia , 2000, British journal of haematology.

[153]  P. Libby Inflammation in atherosclerosis , 2002, Nature.

[154]  T. Wun,et al.  Platelet-erythrocyte adhesion in sickle cell disease. , 1999, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[155]  P. Gane,et al.  The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia. , 2001, Blood.

[156]  S. Rothman,et al.  Sickle cell anemia and central nervous system infarction: A neuropathological study , 1986, Annals of neurology.

[157]  B. Setty,et al.  Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. , 1996, Blood.

[158]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[159]  R. Hebbel,et al.  Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. , 1999, Blood.

[160]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[161]  M. Steinberg,et al.  Modulation of erythrocyte-endothelial interactions and the vasocclusive severity of sickling disorders. , 1981, Blood.

[162]  R. Nagel,et al.  Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. , 1986, Blood.

[163]  A. Morelli,et al.  NCX-4016 (NO-Aspirin) Inhibits Lipopolysaccharide-Induced Tissue Factor Expression In Vivo: Role of Nitric Oxide , 2002, Circulation.

[164]  C. Dampier,et al.  Splenic Arteries and Veins in Pediatric Sickle Cell Disease , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[165]  B. Setty,et al.  Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology. , 2002, The Journal of laboratory and clinical medicine.

[166]  J. Rosa,et al.  Clinical manifestations and erythrocyte adhesion to endothelium in sickle cell syndrome , 1985, American journal of hematology.

[167]  J. Moake,et al.  Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. , 1987, The Journal of clinical investigation.

[168]  C. Dampier,et al.  Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. , 2001, Blood.

[169]  F. Kuypers,et al.  Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. , 2001, Blood.

[170]  L. Dobrucki,et al.  Increased Nitric Oxide Bioavailability in Endothelial Cells Contributes to the Pleiotropic Effect of Cerivastatin , 2002, Circulation.

[171]  J. Laver,et al.  Granulocytosis causing sickle-cell crisis , 1998, The Lancet.

[172]  T. Pearson,et al.  Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF) , 1992, British journal of haematology.

[173]  J. Weil,et al.  Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium , 2000, American journal of hematology.

[174]  K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. , 2000, Cardiovascular research.

[175]  L. Parise,et al.  Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. , 2001, The Journal of clinical investigation.

[176]  R. Hebbel Adhesive interactions of sickle erythrocytes with endothelium. , 1997, The Journal of clinical investigation.

[177]  E. Evans,et al.  Sickle erythrocyte adherence to vascular endothelium. Morphologic correlates and the requirement for divalent cations and collagen-binding plasma proteins. , 1985, The Journal of clinical investigation.

[178]  B. Coller,et al.  Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[179]  M. Fabry,et al.  In Vivo Studies of Sickle Red Blood Cells , 2004, Microcirculation.

[180]  D. Faller,et al.  Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. , 1995, The Journal of clinical investigation.

[181]  A. Takeshita,et al.  Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery. , 2002, American journal of physiology. Heart and circulatory physiology.

[182]  F. Ofosu,et al.  Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patients , 1992, British journal of haematology.

[183]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease , 2002, Nature Medicine.

[184]  J. L. Goodman,et al.  Potentiated adherence of sickle erythrocytes to endothelium infected by virus. , 1987, The Journal of clinical investigation.

[185]  R. Nagel,et al.  Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[186]  M. Steinberg,et al.  RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. , 1997, Blood.

[187]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[188]  WILLIAM H. FRISHMAN,et al.  Role of Infection in Atherosclerosis and Coronary Artery Disease: A New Therapeutic Target? , 1999, Heart disease.

[189]  P. Lauf,et al.  Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. , 1994, Blood.

[190]  Scott T. Miller,et al.  Prediction of adverse outcomes in children with sickle cell disease. , 2000, The New England journal of medicine.

[191]  M. Telen,et al.  Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. , 2003, Blood.

[192]  T. Sugihara,et al.  Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. , 1992, Blood.

[193]  Marie-Luise Brennan,et al.  Myeloperoxidase Functions as a Major Enzymatic Catalyst for Initiation of Lipid Peroxidation at Sites of Inflammation* , 2002, The Journal of Biological Chemistry.